Get the Stockscreener App
14.00
3.45%
-0.50
Tyra Biosciences Inc stock is traded at $14.00, with a volume of 486.13K.
It is down -3.45% in the last 24 hours and down -11.78% over the past month.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
See More
Previous Close:
$14.50
Open:
$14.3
24h Volume:
486.13K
Relative Volume:
1.47
Market Cap:
$708.44M
Revenue:
-
Net Income/Loss:
$-69.13M
P/E Ratio:
-11.67
EPS:
-1.2
Net Cash Flow:
$-50.91M
1W Performance:
-6.29%
1M Performance:
-11.78%
6M Performance:
-17.60%
1Y Performance:
+2.04%
1-Day Range:
$13.88
$14.96
1-Week Range:
$13.88
$15.55
52-Week Range:
$11.24
$29.60
Tyra Biosciences Inc Stock (TYRA) Company Profile
Name
Tyra Biosciences Inc
Sector
Industry
Phone
(619) 728-4760
Address
2656 STATE STREET, CARLSBAD
Compare TYRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
14.00 | 708.44M | 0 | -69.13M | -50.91M | -1.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-18-24 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-15-24 | Initiated | Piper Sandler | Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-23 | Initiated | Wedbush | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Jun-23-22 | Initiated | H.C. Wainwright | Buy |
| Mar-08-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-21 | Downgrade | Jefferies | Buy → Hold |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Oct-11-21 | Initiated | Cowen | Outperform |
| Oct-11-21 | Initiated | Jefferies | Buy |
View All
Tyra Biosciences Inc Stock (TYRA) Latest News
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires New Position in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Wellington Management Group LLP Sells 26,207 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
The Take On Tyra Biosciences (NASDAQ:TYRA) - Seeking Alpha
(TYRA) Trading Signals - Stock Traders Daily
Tyra Biosciences to Present at Upcoming Investor Conferences - The Eastern Progress Online
Charles Schwab Investment Management Inc. Increases Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Frazier Life Sciences Management L.P. Cuts Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) - MarketBeat
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET - Victoria Advocate
Janus Henderson Group PLC Takes Position in Tyra Biosciences, Inc. (NASDAQ:TYRA) - MarketBeat
Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference - The Eastern Progress Online
Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) - The Eastern Progress Online
(TYRA) Investment Analysis - Stock Traders Daily
Polar Asset Management Partners Inc. Buys New Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA) - MarketBeat
Tyra Biosciences to Participate in 2023 Jefferies London Healthc - GuruFocus.com
Walleye Capital LLC Has $2.98 Million Holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA) - MarketBeat
Sio Capital Management LLC Has $9.42 Million Holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA) - MarketBeat
How to Take Advantage of moves in (TYRA) - Stock Traders Daily
Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 5%Here's Why - MarketBeat
Short Interest in Tyra Biosciences, Inc. (NASDAQ:TYRA) Drops By 20.0% - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Shares Gap UpWhat's Next? - MarketBeat
RA Capital Management, L.P. Increases Stake in Tyra Biosciences Inc - GuruFocus.com
Equities Analysts Offer Predictions for TYRA FY2024 Earnings - MarketBeat
Tyra Biosciences to Present FGFR Precision Medicine Updates at Major Healthcare Conferences - StockTitan
FMR LLC Increases Stake in Tyra Biosciences Inc - GuruFocus.com
Tyra Biosciences stock target cut, retains buy rating on clinical data - Investing.com Canada
HC Wainwright Has Lowered Expectations for Tyra Biosciences (NASDAQ:TYRA) Stock Price - MarketBeat
Tyra Biosciences director Nina Kjellson sells $1.28 million in stock By Investing.com - Investing.com Australia
Tyra Biosciences’ Q3 2024: Clinical Progress and Financial Resilience - TipRanks
Tyra Biosciences director Nina Kjellson sells $1.28 million in stock - Investing.com
Tyra Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights - PR Newswire
Tyra Biosciences director Nina S. Kjellson sells shares worth $194k - Investing.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Sold by Auour Investments LLC - MarketBeat
Long Term Trading Analysis for (TYRA) - Stock Traders Daily
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up After Insider Buying Activity - MarketBeat
Tyra Biosciences director Nina Kjellson sells $2.28m in stock By Investing.com - Investing.com Australia
Tyra Biosciences director Nina Kjellson sells $2.28m in stock - Investing.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) CFO Purchases $152,000.00 in Stock - MarketBeat
Tyra Biosciences CFO Alan Fuhrman acquires $151,954 in stock By Investing.com - Investing.com South Africa
Tyra Biosciences CFO Alan Fuhrman acquires $151,954 in stock - Investing.com
TYRA-300 shows encouraging safety, efficacy in FGFR3+ metastatic urothelial carcinoma - Urology Times
Tyra Biosciences (NASDAQ:TYRA) Trading Down 10.2%Here's What Happened - MarketBeat
Tyra Biosciences advances with Phase 2 trial for achondroplasia treatment By Investing.com - Investing.com Australia
Tyra Biosciences advances with Phase 2 trial for achondroplasia treatment - Investing.com
Piper Sandler maintains Overweight on Tyra Biosciences stock By Investing.com - Investing.com Canada
Tyra Biosciences stock target lifted, retains buy on clinical trial data - Investing.com Canada
Tyra Biosciences Inc Stock (TYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):